VENBIO PARTNERS LLC
Q3 2023 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001776382
· CRD 290045
· Exempt reporting adviser
$352.7M Reported Value Total
Exempt Reporting Adviser
WWW.VENBIO.COM
Source: Form ADV filed 2026-03-12
Reported value
$352.7M
Quarter over quarter
-18.0%
Holdings
8
Top-10 concentration
100.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
David Pezeshki
Chief Financial Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2023 13F record
Q3 2023 13F filing summary
| Period of report | September 30, 2023 |
|---|---|
| Filed | November 14, 2023 |
| Form | 13F-HR |
| Reported value | $352.7M |
| Positions | 8 |
| Change in reported value | +27.6% |
| New positions | 1 |
| Exited positions | 0 |
| Position turnover | 12.5% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
9 | $495.9M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
7 | $519.4M |
|
Q1 2026 13F
Filed May 15, 2026
|
6 | $280.6M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
6 | $216.3M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
6 | $176.4M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
6 | $114.8M |
|
Q1 2025 13F
Filed May 15, 2025
|
7 | $123.6M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
7 | $170.7M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
6 | $194.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
6 | $231.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
5 | $281.9M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
7 | $667.2M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
8 | $352.7M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
7 | $276.3M |
|
Q1 2023 13F
Filed May 15, 2023
|
6 | $180.4M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
7 | $322.5M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
8 | $432.2M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
9 | $351.2M |
|
Q1 2022 13F
Filed May 16, 2022
|
10 | $451.1M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
9 | $555.1M |
12 earlier quarters on file — choose one from the quarter menu above.
Top 8 holdings · Q3 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RYZB RAYZEBIO INC | $114.5M | 32.47% |
| 2 | PHVS PHARVARIS N V | $89.0M | 25.24% |
| 3 | ALXO ALX ONCOLOGY HLDGS INC | $46.6M | 13.2% |
| 4 | SLRN ACELYRIN INC | $39.2M | 11.11% |
| 5 | HRMY HARMONY BIOSCIENCES HLDGS IN | $33.9M | 9.62% |
| 6 | VTYX VENTYX BIOSCIENCES INC | $26.4M | 7.47% |
| 7 | ELEV ELEVATION ONCOLOGY INC | $1.9M | 0.55% |
| 8 | IMPL IMPEL PHARMACEUTICALS INC | $1.2M | 0.34% |
Values as reported on the Q3 2023 Form 13F. Every position is in the holdings table below.